Table 3

Potencies of 5-HT1A ligands to substitute in rats and pigeons trained to discriminate 8-OH-DPAT from saline

CompoundDose rangeDrug-Appropriate SelectionRate of Responding
nED5095% C.L.maxED5095% C.L.max (mean ± S.E.M.)
mg/kg mg/kg % mg/kg (%)
Rat
 BMY-73780.04–2.590.940.32–2.7800.570.20–1.73.8  ± 1.4
 Idazoxan2.5–1076.72.5–18673.21.2–8.336  ± 15
 LEK88043-a 0.010–0.1690.0890.035–0.23800.0370.015–0.09029  ± 13
 Yohimbine0.63–1073.40.91–13751.80.70–4.70.9  ± 0.4
 Lisuride0.0025–0.047>0.04600.00580.0027–0.01221  ± 6.5
 Eltoprazine0.63–2.57>2.5570.760.46–1.220  ± 8.4
Pigeon
 BMY-73780.16–107>10291.70.59–4.658  ± 12
 Idazoxan0.63–407>40297.32.9–1913  ± 13
 LEK88040.01–0.167>0.16290.0480.021–0.1118  ± 18
 Yohimbine0.16–2.57>2.5330.260.11–0.610  ± 0
 Lisuride0.0025–0.0470.0070.0028–0.0191000.0200.0059–0.06561  ± 17
 Eltoprazine0.63–1071.20.58–2.51003.51.3–9.017  ± 17
  • 3-a Drug-lever selection results have been reported elsewhere (Kleven et al., 1997).